Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012158249> ?p ?o ?g. }
- W2012158249 endingPage "11080" @default.
- W2012158249 startingPage "11064" @default.
- W2012158249 abstract "Serological thymidine kinase 1 (STK1) is a reliable proliferation marker for prognosis, monitoring tumour therapy, and relapse. Here we investigated the use of STK1 in health screening for early detection of pre-malignant and malignant diseases. The investigation was based on 35,365 participants in four independent health screening studies in China between 2005–2011. All participants were clinically examined. The concentration of STK1 was determined by a sensitive chemiluminescent dot blot ECL assay. The ROCvalue of the STK1 assay was 0.96. At a cut-off STK1 value of 2.0 pM, the likelihood (+) value was 236.5, and the sensitivity and the specificity were 0.78 and 0.99, respectively. The relative number of city-dwelling people with elevated STK1 values (≥2.0 pM) was 0.8% (198/26,484), while the corresponding value for the group of oil-field workers was 5.8% (514/8,355). The latter group expressed significantly higher frequency of refractory anaemia, fatty liver, and obesity, compared to the city dwellers, but no cases of breast hyperplasia or prostate hyperplasia. Furthermore, people working in oil drilling/oil transportation showed higher STK1 values and higher frequency of pre-malignancies and benign diseases than people working in the oil-field administration. In the STK1 elevated group of the city-dwelling people, a statistically significantly higher number of people were found to have malignancies, pre-malignancies of all types, moderate/severe type of hyperplasia of breast or prostate, or refractory anaemia, or to be at high risk for hepatitis B, compared to people with normal STK1 values (< 2.0 pM). No malignancies were found in the normal STK1 group. In the elevated STK1 group 85.4% showed diseases linked to a higher risk for pre-/early cancerous progression, compared to 52.4% of those with normal STK1 values. Among participants with elevated STK1 values, 8.8% developed new malignancies or progress in their pre-malignancies within 5 to 72 months, compared to 0.2% among people with normal STK1 values. People who showed elevated STK1 values were at about three to five times higher risk to develop malignancies compared to a calculated risk based on a cancer incidence rate of 0.2–0.3%. We conclude that serological TK1 protein concentration is a reliable marker for risk assessment of pre/early cancerous progression." @default.
- W2012158249 created "2016-06-24" @default.
- W2012158249 creator A5006355069 @default.
- W2012158249 creator A5006402277 @default.
- W2012158249 creator A5006655484 @default.
- W2012158249 creator A5008200354 @default.
- W2012158249 creator A5019298727 @default.
- W2012158249 creator A5031790789 @default.
- W2012158249 creator A5037458498 @default.
- W2012158249 creator A5042321098 @default.
- W2012158249 creator A5049169322 @default.
- W2012158249 creator A5053697731 @default.
- W2012158249 creator A5081612516 @default.
- W2012158249 creator A5087478688 @default.
- W2012158249 date "2011-11-28" @default.
- W2012158249 modified "2023-09-26" @default.
- W2012158249 title "Serological Thymidine Kinase 1 is a Biomarker for Early Detection of Tumours—A Health Screening Study on 35,365 People, Using a Sensitive Chemiluminescent Dot Blot Assay" @default.
- W2012158249 cites W107315917 @default.
- W2012158249 cites W1818662343 @default.
- W2012158249 cites W1924224369 @default.
- W2012158249 cites W1961467486 @default.
- W2012158249 cites W1968815011 @default.
- W2012158249 cites W1968895848 @default.
- W2012158249 cites W1969566389 @default.
- W2012158249 cites W1978483112 @default.
- W2012158249 cites W1991696977 @default.
- W2012158249 cites W1993355923 @default.
- W2012158249 cites W2014213368 @default.
- W2012158249 cites W2026248332 @default.
- W2012158249 cites W2040117805 @default.
- W2012158249 cites W2058017302 @default.
- W2012158249 cites W2060542207 @default.
- W2012158249 cites W2063622539 @default.
- W2012158249 cites W2063785218 @default.
- W2012158249 cites W2089011168 @default.
- W2012158249 cites W2089165045 @default.
- W2012158249 cites W2089258364 @default.
- W2012158249 cites W2094388623 @default.
- W2012158249 cites W2099445744 @default.
- W2012158249 cites W2106008859 @default.
- W2012158249 cites W2110256671 @default.
- W2012158249 cites W2155052327 @default.
- W2012158249 cites W2155243100 @default.
- W2012158249 cites W4240114294 @default.
- W2012158249 doi "https://doi.org/10.3390/s111211064" @default.
- W2012158249 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3251970" @default.
- W2012158249 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22247653" @default.
- W2012158249 hasPublicationYear "2011" @default.
- W2012158249 type Work @default.
- W2012158249 sameAs 2012158249 @default.
- W2012158249 citedByCount "47" @default.
- W2012158249 countsByYear W20121582492012 @default.
- W2012158249 countsByYear W20121582492013 @default.
- W2012158249 countsByYear W20121582492014 @default.
- W2012158249 countsByYear W20121582492015 @default.
- W2012158249 countsByYear W20121582492016 @default.
- W2012158249 countsByYear W20121582492018 @default.
- W2012158249 countsByYear W20121582492019 @default.
- W2012158249 countsByYear W20121582492020 @default.
- W2012158249 countsByYear W20121582492021 @default.
- W2012158249 countsByYear W20121582492022 @default.
- W2012158249 countsByYear W20121582492023 @default.
- W2012158249 crossrefType "journal-article" @default.
- W2012158249 hasAuthorship W2012158249A5006355069 @default.
- W2012158249 hasAuthorship W2012158249A5006402277 @default.
- W2012158249 hasAuthorship W2012158249A5006655484 @default.
- W2012158249 hasAuthorship W2012158249A5008200354 @default.
- W2012158249 hasAuthorship W2012158249A5019298727 @default.
- W2012158249 hasAuthorship W2012158249A5031790789 @default.
- W2012158249 hasAuthorship W2012158249A5037458498 @default.
- W2012158249 hasAuthorship W2012158249A5042321098 @default.
- W2012158249 hasAuthorship W2012158249A5049169322 @default.
- W2012158249 hasAuthorship W2012158249A5053697731 @default.
- W2012158249 hasAuthorship W2012158249A5081612516 @default.
- W2012158249 hasAuthorship W2012158249A5087478688 @default.
- W2012158249 hasBestOaLocation W20121582491 @default.
- W2012158249 hasConcept C126322002 @default.
- W2012158249 hasConcept C159654299 @default.
- W2012158249 hasConcept C203014093 @default.
- W2012158249 hasConcept C45189115 @default.
- W2012158249 hasConcept C71924100 @default.
- W2012158249 hasConcept C90924648 @default.
- W2012158249 hasConceptScore W2012158249C126322002 @default.
- W2012158249 hasConceptScore W2012158249C159654299 @default.
- W2012158249 hasConceptScore W2012158249C203014093 @default.
- W2012158249 hasConceptScore W2012158249C45189115 @default.
- W2012158249 hasConceptScore W2012158249C71924100 @default.
- W2012158249 hasConceptScore W2012158249C90924648 @default.
- W2012158249 hasIssue "12" @default.
- W2012158249 hasLocation W20121582491 @default.
- W2012158249 hasLocation W20121582492 @default.
- W2012158249 hasLocation W20121582493 @default.
- W2012158249 hasLocation W20121582494 @default.
- W2012158249 hasLocation W20121582495 @default.
- W2012158249 hasOpenAccess W2012158249 @default.
- W2012158249 hasPrimaryLocation W20121582491 @default.
- W2012158249 hasRelatedWork W1569996386 @default.
- W2012158249 hasRelatedWork W2047381680 @default.